129 related articles for article (PubMed ID: 38167755)
1. Counterpoint: Why the FDA Should Not Regulate Laboratory-Developed Tests.
Leung ML
J Appl Lab Med; 2024 Jan; 9(1):155-158. PubMed ID: 38167755
[No Abstract] [Full Text] [Related]
2. FDA regulation of laboratory-developed diagnostic tests: protect the public, advance the science.
Sharfstein J
JAMA; 2015 Feb; 313(7):667-8. PubMed ID: 25560381
[No Abstract] [Full Text] [Related]
3. FDA oversight of laboratory-developed tests: is it necessary, and how would it impact clinical laboratories?
Scott MG; Ashwood ER; Annesley TM; Leonard DG; Burgess MC
Clin Chem; 2013 Jul; 59(7):1017-22. PubMed ID: 23536512
[No Abstract] [Full Text] [Related]
4. FDA announces plans to regulate LDTs.
Cancer Discov; 2014 Nov; 4(11):1250. PubMed ID: 25367935
[No Abstract] [Full Text] [Related]
5. FDA regulation of LDTs--an update.
Jones PM
MLO Med Lab Obs; 2015 Sep; 47(9):18-9. PubMed ID: 26495591
[No Abstract] [Full Text] [Related]
6. Looming regulations and FDA oversight mean an uncertain reimbursement climate in 2016.
Wolf R
MLO Med Lab Obs; 2016 May; 48(5):26-7. PubMed ID: 27323455
[No Abstract] [Full Text] [Related]
7. US Food and Drug Administration regulatory oversight of laboratory-developed tests: Commentary on the draft guidance.
Sidawy MK
Cancer Cytopathol; 2015 Oct; 123(10):573-5. PubMed ID: 26042383
[No Abstract] [Full Text] [Related]
8. Point: The Need for Additional FDA Regulations in Laboratory Medicine.
Konnick EQ
J Appl Lab Med; 2024 Jan; 9(1):151-154. PubMed ID: 38167766
[No Abstract] [Full Text] [Related]
9. FDA Announces Increased Oversight of Some Diagnostic Laboratory Tests.
Harris E
JAMA; 2024 Jun; 331(24):2071. PubMed ID: 38819803
[No Abstract] [Full Text] [Related]
10. "Research use only" reagents: is there an imperative for increased FDA oversight?
O'Leary TJ
Clin Chem; 2011 Dec; 57(12):1681-3. PubMed ID: 21998341
[No Abstract] [Full Text] [Related]
11. Laboratory-developed tests are not the practice of medicine.
Allen JS
MLO Med Lab Obs; 2015 Sep; 47(9):46. PubMed ID: 26495599
[No Abstract] [Full Text] [Related]
12. Tighter gene tests.
Fox J
Nat Biotechnol; 2008 Jul; 26(7):721. PubMed ID: 18612277
[No Abstract] [Full Text] [Related]
13. Does Increased Regulation of Laboratory-Developed Tests (LDTs) Make Sense? The Harms of Over-Regulation.
Hortin GL
J Appl Lab Med; 2024 May; 9(3):646-650. PubMed ID: 38332567
[No Abstract] [Full Text] [Related]
14. FDA Oversight of Laboratory-Developed Tests: Where Are We Now?
Gatter K
Arch Pathol Lab Med; 2017 Jun; 141(6):746-748. PubMed ID: 28557601
[No Abstract] [Full Text] [Related]
15. The FDA's Experience with Covid-19 Antibody Tests.
Shuren J; Stenzel T
N Engl J Med; 2021 Feb; 384(7):592-594. PubMed ID: 33605568
[No Abstract] [Full Text] [Related]
16. Laboratory developed tests: what may be coming.
Jones PM
MLO Med Lab Obs; 2012 Oct; 44(10):24, 26. PubMed ID: 23091959
[No Abstract] [Full Text] [Related]
17. FDA oversight of laboratory-developed tests will facilitate adoption of pharmacogenetic testing into routine clinical care.
Hillebrenner E; Litwack E; Bradley P; Donigan K; Lowe T; Serrano K; Kelm K; Mansfield E; Gutierrez A
J Clin Pharmacol; 2015 Jul; 55(7):728-30. PubMed ID: 26053648
[No Abstract] [Full Text] [Related]
18. Theranos Experience Exposes Weaknesses in FDA Regulatory Discretion.
Jotwani R; Boumil M; Salem D; Wetterhahn M; Beninger P
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):433-438. PubMed ID: 28741304
[No Abstract] [Full Text] [Related]
19. How will the FDA impact the laboratory developed test?
Davis J; Wentz J
Clin Lab Sci; 2007; 20(3):130-1. PubMed ID: 17691668
[No Abstract] [Full Text] [Related]
20. FDA and CLIA oversight of advanced diagnostics and biomarker tests.
Terry SF
Genet Test Mol Biomarkers; 2010 Jun; 14(3):285-7. PubMed ID: 20578940
[No Abstract] [Full Text] [Related]
[Next] [New Search]
